A cytokine-neutralizing antibody as a structural mimetic of 2 receptor interactions

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 51, 2008, Pages 20251-20256

  Grütter, Christian ^a   Wilkinson, Trevor ^b   Turner, Richard ^b   Podichetty, Sadhana ^b   Finch, Donna ^b   McCourt, Matthew ^b   Loning, Scott ^c   Jermutus, Lutz ^b   Grütter, Markus G ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b MEDIMMUNE   (United States)

^c GENZYME CORPORATION   (United States)

Author keywords

Cancer; Fibrotic diseases; TGF signaling; TGF antibody complex; X ray structure

Indexed keywords

EPITOPE; ISOPROTEIN; NEUTRALIZING ANTIBODY; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2;

ANIMAL CELL; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CRYSTAL STRUCTURE; MOLECULAR INTERACTION; MOLECULAR MODEL; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANTIBODIES; CYTOKINES; EPITOPES; HUMANS; MOLECULAR MIMICRY; PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3;

EID: 58149484859     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0807200106     Document Type: Article

References (44)

1. Massague J (1990) The transforming growth factor-beta family. Annu Rev Cell Biol 6:597-641.
2. Roberts AB, Sporn MB (1990) in Peptide Growth Factors and their Receptors, eds Roberts AB, Sporn MB (Springer, Heidelberg), pp 421-472.
3. Daopin S, Li M, Davies DR (1993) Crystal structure of TGF-beta 2 refined at 1.8 A resolution. Proteins 17:176-192.
4. Hinck AP, et al. (1996) Transforming growth factor beta 1: Three-dimensional structure in solution and comparison with the X-ray structure of transforming growth factor beta 2. Biochemistry 35:8517-8534.
5. Mittl PR, et al. (1996) The crystal structure of TGF-beta 3 and comparison to TGF-beta 2: Implications for receptor binding. Protein Sci 5:1261-1271.
6. Nickel J, Kotzsch A, Sebald W, Mueller TD (2005) A single residue of GDF-5 defines binding specificity to BMP receptor IB. J Mol Biol 349:933-947.
7. Scheufler C, Sebald W, Hulsmeyer M (1999) Crystal structure of human bone morphogenetic protein-2 at 2.7 A resolution. J Mol Biol 287:103-115.
8. Schlunegger MP, Grutter MG (1993) Refined crystal structure of human transforming growth factor beta 2 at 1.95 A resolution. J Mol Biol 231:445-458.
9. Koli K, et al. (2001) Latency, activation, and binding proteins of TGF-beta. Microsc Res Tech 52:354-362.
10. Munger JS, et al. (1997) Latent transforming growth factor-beta: Structural features and mechanisms of activation. Kidney Int 51:1376-1382.
11. Bartram U, et al. (2001) Double-outlet right ventricle and overriding tricuspid valve reflect disturbances of looping, myocardialization, endocardial cushion differentiation, and apoptosis in TGF-beta(2)-knockout mice. Circulation 103:2745-2752.
12. Kulkarni AB, Karlsson S (1993) Transforming growth factor-beta 1 knockout mice. A mutation in one cytokine gene causes a dramatic inflammatory disease Am J Pathol 143:3-9.
13. Proetzel G, et al. (1995) Transforming growth factor-beta 3 is required for secondary palate fusion. Nat Genet 11:409-414.
14. Groppe J, et al. (2008) Cooperative assembly of TGF-beta superfamily signaling complexes is mediated by two disparate mechanisms and distinct modes of receptor binding. Mol Cell 29:157-168.
15. Wrana JL, et al. TGF beta signals through a heteromeric protein kinase receptor complex (1992) Cell 71:1003-1014.
16. Cheifetz S, et al. (1990) Distinct transforming growth factor-beta (TGF-beta) receptor subsets as determinants of cellular responsiveness to three TGF-beta isoforms. J Biol Chem 265:20533-20538.
17. Zuniga JE, et al. (2005) Assembly of TbetaRI:TbetaRII:TGFbeta ternary complex in vitro with receptor extracellular domains is cooperative and isoform-dependent. J Mol Biol 354:1052-1068.
18. Sankar S, et al. (1995) Expression of transforming growth factor type III receptor in vascular endothelial cells increases their responsiveness to transforming growth factor beta 2. J Biol Chem 270:13567-13572.
19. Wrana JL, et al. Mechanism of activation of the TGF-beta receptor (1994) Nature 370:341-347.
20. Shi Y, Massague J (2003) Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113:685-700.
21. ten Dijke P, Miyazono K, Heldin CH (2000) Signaling inputs converge on nuclear effectors in TGF-beta signaling. Trends Biochem Sci 25:64-70.
22. Chung KF (2006) Cytokines as targets in chronic obstructive pulmonary disease. Curr Drug Targets 7:675-681.
23. Lijnen PJ, Petrov VV, Fagard RH (2000) Induction of cardiac fibrosis by transforming growth factor-beta(1). Mol Genet Metab 71:418-435.
24. Blobe GC, Schiemann WP, Lodish HF (2000) Role of transforming growth factor beta in human disease. N Engl J Med 342:1350-1358.
25. Yu L, Border WA, Huang Y, Noble NA (2003) TGF-beta isoforms in renal fibrogenesis. Kidney Int 64:844-856.
26. Siegel PM, Massague J (2003) Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 3:807-821.
27. Tang B, et al. (2003) TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J Clin Invest 112:1116-1124.
28. Arteaga CL (2006) Inhibition of TGFbeta signaling in cancer therapy. Curr Opin Genet Dev 16:30-37.
29. Iyer S, et al. (2005) Targeting TGFbeta signaling for cancer therapy. Cancer Biol Ther 4:261-266.
30. Saunier EF, Akhurst RJ (2006) TGF beta inhibition for cancer therapy. Curr Cancer Drug Targets 6:565-578.
31. Liu VC, et al. (2007) Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: Role of tumor-derived TGF-beta. J Immunol 178:2883-2892.
32. Terabe M, et al. (2003) Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: Abrogation prevents tumor recurrence. J Exp Med 198:1741-1752.
33. Günther A, Markart P, Eickelberg O, Seeger W (2006) Pulmonary fibrosis - A therapeutic dilemma? Med Klin (Munich) 101:308-312.
34. Kabat EA, Wu TT (1991) Identical V region amino acid sequences and segments of sequences in antibodies of different specificities. Relative contributions of VH and VL genes, minigenes, and complementarity-determining regions to binding of antibody-combining sites. J Immunol 147:1709-1719.
35. Bocharov EV, et al. (2000) Sequence-specific 1H and 15N assignment and secondary structure of transforming growth factor beta3. J Biomol NMR 16:179-180.
36. Pellaud J, Schote U, Arvinte T, Seelig J (1999) Conformation and self-association of human recombinant transforming growth factor-beta3 in aqueous solutions. J Biol Chem 274:7699-7704.
37. Hart PJ, et al. (2002) Crystal structure of the human TbetaR2 ectodomain - TGF-beta3 complex. Nat Struct Biol 9:203-208.
38. Cerletti N (1995) Novel process for the production of biologically active dimeric protein. EP 95/02718 MX9700656 (A): 1-85.
39. Kabsch W (1993) Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. J Appl Crystallogr 26:795-800.
40. Read RJ (2001) Pushing the boundaries of molecular replacement with maximum likelihood. Acta Crystallogr D 57:1373-1382.
41. Brunger AT, et al. (1998) Crystallography and NMR system: A new software suite for macromolecular structure determination Acta Crystallogr D 54 (Pt 5):905-921.
42. Emsley P, Cowtan K (2004) Coot: Model-building tools for molecular graphics. Acta Crystallogr D 60:2126-2132.
43. Laskowski RA, McArthur MW, Moss DS, Thornton JM (1993) PROCHECK: A program to check the stereochemical quality of protein structures. J Appl Crystallogr 26:263-291.
44. Danielpour D, et al. (1989) Immunodetection and quantitation of the two forms of transforming growth factor-beta (TGF-beta 1 and TGF-beta 2) secreted by cells in culture. J Cell Physiol 138:79-86.